Genetics in Medicine — Progress and Pitfalls
By Editorial,
The Lancet
| 06. 06. 2015
Untitled Document
Last week, the White House decreed that human germline gene editing in biomedical research is discontinued in the USA until ethical and safety concerns are resolved. This technology involves modification of the genome in germ cells, which can then be inherited and passed on to future generations. “The administration believes that altering the human germline for clinical purposes is a line that should not be crossed at this time”, said John P Holdren, Director of the White House Office of Science and Technology Policy.
In recent years, genome engineering technology has developed the ability to edit DNA more precisely than before. The new technology is based on an enzyme complex that binds and splices DNA at precise locations, and can target a dysfunctional gene by first deleting, then repairing or replacing the target sequence with another molecule. One such technique, CRISPR/Cas—short for clustered regularly interspaced short palindromic repeats—has received attention after a study from China used the technique for the first time to edit nonviable human embryos to disable the gene for β-thalassaemia. However, the study...
Related Articles
By staff, Japan Times | 12.04.2025
Japan plans to introduce a ban with penalties on implanting a genome-edited fertilized human egg into the womb of a human or another animal amid concerns over "designer babies."
A government expert panel broadly approved a proposal, including the ban...
By David Jensen, The California Stem Cell Report | 12.11.2025
California’s stem cell and gene therapy agency today approved spending $207 million more on training and education, sidestepping the possibility of using the cash to directly support revolutionary research that has been slashed and endangered by the Trump administration.
Directors...
By Tina Stevens, CounterPunch | 12.11.2025
Silicon Valley and other high tech billionaires are investing millions in start-ups dedicated to creating genetically engineered (GE) babies, according to a recent Wall Street Journal (WSJ) report. AI mogul Sam Altman, cryptocurrency entrepreneur Brian Armstrong, venture capitalist Peter...
By Jenny Lange, BioNews | 12.01.2025
A UK toddler with a rare genetic condition was the first person to receive a new gene therapy that appears to halt disease progression.
Oliver, now three years old, has Hunter syndrome, an inherited genetic disorder that leads to physical...